<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00911586</url>
  </required_header>
  <id_info>
    <org_study_id>CLAR-09009</org_study_id>
    <nct_id>NCT00911586</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study to Determine Time to Steady-state</brief_title>
  <official_title>Pharmacokinetic Study to Determine Time to Steady-state of an Oral Testosterone Undecanoate Formulation in Hypogonadal Men.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clarus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clarus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to confirm how long (i.e., how many days) it takes to reach&#xD;
      steady-state when testosterone undecanoate is administered twice daily.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serum testosterone levels will be obtained in hypogonadal (serum testosterone &lt;300 ng/dL)&#xD;
      males receiving testosterone undecanoate capsules administered twice daily. Serum samples&#xD;
      will be obtained consecutively in the morning on several days during one month of open-label&#xD;
      treatment to confirm the time at which steady-state is reached.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum T Concentration at Steady State</measure>
    <time_frame>pre-dose on Days 1, 3, 5, 6, and 7</time_frame>
    <description>Serum T at steady state by evaluating the day-to-day changes in pre-dose concentrations on Days 1, 3, 5, 6, and 7 of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum T Concentration at Steady-State</measure>
    <time_frame>pre-dose on Days 10, 14, 17, 21, 24, 27, and 28</time_frame>
    <description>Serum T at steady-state by evaluating the day-to-day changes in pre-dose concentrations on Days 10, 14, 17, 21, 24, 27, and 28 of treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Male Hypogonadism</condition>
  <condition>Primary Hypogonadism</condition>
  <condition>Secondary Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Testosterone Undecanoate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone undecanoate</intervention_name>
    <arm_group_label>Testosterone Undecanoate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, age 18-75&#xD;
&#xD;
          -  Morning serum testosterone (T) &lt;300 ng/dL on two occasions&#xD;
&#xD;
          -  Naive to androgen-replacement therapy or willing to wash-out from current T therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant intercurrent disease&#xD;
&#xD;
          -  Abnormal prostate digital rectal exam, elevated PSA, AUA symptom score &gt;15 or history&#xD;
             of prostate cancer.&#xD;
&#xD;
          -  Serum transaminases &gt;2 times upper limit of normal&#xD;
&#xD;
          -  Serum bilirubin &gt;2.0 mg/dL&#xD;
&#xD;
          -  Hematocrit &lt;35% or &gt;50%&#xD;
&#xD;
          -  BMI &gt;36&#xD;
&#xD;
          -  Untreated, obstructive sleep apnea.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Flippo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alabama Clinical Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 29, 2009</study_first_submitted>
  <study_first_submitted_qc>May 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2009</study_first_posted>
  <results_first_submitted>August 31, 2020</results_first_submitted>
  <results_first_submitted_qc>December 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2020</results_first_posted>
  <disposition_first_submitted>August 17, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 17, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 19, 2010</disposition_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Testosterone Undecanoate</title>
          <description>Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days.&#xD;
Testosterone undecanoate: Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Testosterone Undecanoate</title>
          <description>Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days.&#xD;
Testosterone undecanoate: Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" spread="10.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum T Concentration at Steady State</title>
        <description>Serum T at steady state by evaluating the day-to-day changes in pre-dose concentrations on Days 1, 3, 5, 6, and 7 of treatment.</description>
        <time_frame>pre-dose on Days 1, 3, 5, 6, and 7</time_frame>
        <population>All participants were included in the analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Undecanoate</title>
            <description>Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days.&#xD;
Testosterone undecanoate</description>
          </group>
        </group_list>
        <measure>
          <title>Serum T Concentration at Steady State</title>
          <description>Serum T at steady state by evaluating the day-to-day changes in pre-dose concentrations on Days 1, 3, 5, 6, and 7 of treatment.</description>
          <population>All participants were included in the analysis population</population>
          <units>ng/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.077" spread="16.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Part 1 of piecewise linear regression model.</non_inferiority_desc>
            <p_value>0.8060</p_value>
            <method>Regression, Linear</method>
            <method_desc>Part 1 of piecewise linear regression model.</method_desc>
            <param_type>Slope</param_type>
            <param_value>-4.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>16.020</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Part 1 of piecewise linear regression model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum T Concentration at Steady-State</title>
        <description>Serum T at steady-state by evaluating the day-to-day changes in pre-dose concentrations on Days 10, 14, 17, 21, 24, 27, and 28 of treatment.</description>
        <time_frame>pre-dose on Days 10, 14, 17, 21, 24, 27, and 28</time_frame>
        <population>All participants were included in the analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Undecanoate</title>
            <description>Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum T Concentration at Steady-State</title>
          <description>Serum T at steady-state by evaluating the day-to-day changes in pre-dose concentrations on Days 10, 14, 17, 21, 24, 27, and 28 of treatment.</description>
          <population>All participants were included in the analysis population</population>
          <units>ng/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.114" spread="18.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Part 2 of piecewise linear regression model.</non_inferiority_desc>
            <p_value>0.8286</p_value>
            <method>Regression, Linear</method>
            <method_desc>Part 2 of piecewise linear regression model.</method_desc>
            <param_type>Slope</param_type>
            <param_value>4.114</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.456</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Part 2 of piecewise linear regression model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Testosterone Undecanoate</title>
          <description>Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days.&#xD;
Testosterone undecanoate: Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MeDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Belching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Stomach bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritabililty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lower Extremity Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout Flareup</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert E. Dudley, PhD, CEO and President</name_or_title>
      <organization>Clarus Therapeutics, Inc.</organization>
      <phone>847-562-4300</phone>
      <email>rdudley@clarustherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

